PCM
BPMC

Penserra Capital Management’s Blueprint Medicines BPMC Stock Holding History

Penserra Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-474
Closed -$43K – 1020
2020
Q3 		$43K Buy
+474
New +$36.5K ﹤0.01% 645

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Penserra Capital Management's BPMC Position: Q4 2020 in Review

Penserra Capital Management sold out of Blueprint Medicines (BPMC) in Q4 2020, closing a stake of 474 shares — an estimated $43K sold.

Penserra Capital Management first reported a position in BPMC in Q3 2020 and held it in 1 quarter. The position peaked at $43K in Q3 2020. 278 funds tracked by Wall St. Rank hold BPMC as of Q4 2020.

  • Penserra Capital Management reported no remaining Blueprint Medicines position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 474 Blueprint Medicines shares in Q4 2020, an estimated $43K.
  • Penserra Capital Management first reported a position in Blueprint Medicines in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Blueprint Medicines position peaked at $43K in Q3 2020.
  • 278 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.